RAD51 foci formation had been proposed as a predictive biomarker of PARPi response; however, the assay required tumor biopsies either collected after patient exposure to DNA damaging agents or irradiated ex vivo (Graeser et al, 2010; Naipal et al, 2014). The gene discussed is RAD51; the disease is neoplasm.